Abbvie-Header Abbvie-Header

X

Find Drugs for Sleep in Phase II Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Reboxetine

            Therapeutic Area: Sleep Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Axsome Therapeutics

            Deal Size: $331.0 million Upfront Cash: $3.0 million

            Deal Type: Licensing Agreement January 13, 2020

            Details:

            Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy which expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia

            Virtual BoothTransforming oral delivery challenges into proprietary product solutions.

            Contact the Supplier

            Lead Product(s): Mazindol

            Therapeutic Area: Sleep Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: NLS Pharmaceutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 13, 2020

            Details:

            NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aroxybutynin,Atomoxetin

            Therapeutic Area: Sleep Product Name: AD109

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Morningside Ventures

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing March 25, 2021

            Details:

            The proceeds will support Apnimed’s ongoing development and commercialization plans. The company is advancing its lead program, AD109, an oral disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea, which is currently in late-stage Phase 2 clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aroxybutynin,Atomoxetin

            Therapeutic Area: Sleep Product Name: AD109

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 24, 2020

            Details:

            First patient has been dosed in first Phase 2 clinical trial evaluating AD109, the company’s first-in-class, oral pharmaceutical under development for the treatment of OSA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Reboxetine

            Therapeutic Area: Sleep Product Name: AXS-12

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 21, 2020

            Details:

            The expedited development plan includes one Phase 3 efficacy trial, which, along with the previously completed Phase 2 CONCERT trial, will be used to support the filing of an NDA (New Drug Application) for approval of AXS-12 for the treatment of cataplexy in narcolepsy.